Teva Pharmaceutical weakness a buying opportunity, says Cowen
Cowen said Teva concerns regarding copaxone generics and 2011 growth are overdone. The firm reiterates its Outperform rating and recommends initiating positions. :theflyonthewall.com
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.